Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs

Case ID:
C13696
Disclosure Date:
6/15/2015
Description:
Some glutamine antagonists have been shown to have anti-cancer activities in multiple preclinical and clinical studies. However the toxicity of the glutamine antagonists at doses necessary for their anticancer effects have hampered their clinical development. Herein we describe a completely novel use for the glutamine antagonists. Using a prototype glutamine antagonist, we show for the first time, at doses significantly less that that used for its anticancer efficacy, that it can selectively abrogate cognitive deficits in the EcoHIV model of neuroAIDs. We show supporting PK and biomarker data. These data predict the use of glutamine antagonists (or their prodrugs or analogs) for the treatment of cognitive deficits in general, and specifically for NeuroAIDs.
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs PCT: Patent Cooperation Treaty Canada 2,994,162   7/29/2016     Pending
Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs PCT: Patent Cooperation Treaty European Patent Office 16833636.0   7/29/2016     Pending
Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs PCT: Patent Cooperation Treaty China 201680058228.3   7/29/2016     Pending
Glutamine Antagonists for the Treatment of Cognitive Deficits, including NeuroAIDs CIP: Continuation-in-part United States 15/884,974 1/31/2018     Pending
Inventors:
Category(s):
For Information, Contact:
Carole Burns
cburns21@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum